Table 4.
Univariate and multivariate Cox proportional hazard models for PFS.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR | P-value | HR | P-value | |
| PS ≥ 1 | 1.27 (0.95–1.70) | 0.1074 | ||
| Age ≥ 71 (years) | 1.37 (1.07–1.76) | 0.0139* | 1.16 (0.89–1.52) | 0.2616 |
| cT ≥ 3 | 1.18 (0.91–1.54) | 0.2100 | ||
| cN1 (+) | 1.38 (1.00–1.91) | 0.0498 | ||
| Hb ≥ 13.1 (g/dL) | 0.86 (0.66–1.12) | 0.2566 | ||
| PSADT < 10 (months) | 1.42 (1.09–1.82) | 0.0085* | ||
| PSADT < 6 (months) | 1.41 (1.05–1.93) | 0.0249* | ||
| PSADT < 2.85 (months) | 2.06 (1.47–2.89) | < 0.0001* | 2.07 (1.47–2.91) | < 0.0001* |
| PSA ≥ 3.3 (ng/dL) | 0.99 (0.78–1.26) | 0.9483 | ||
| NHT vs. vintage | 0.39 (0.30–0.49) | < 0.0001* | 0.38 (0.29–0.49) | < 0.0001* |
NHT novel hormonal therapy, cN1 clinical positive pelvic lymph node metastasis, cT stage clinical T stage, Hb hemoglobin, HR hazard ratio, PS performance status, PFS progression-free survival, PSA prostate-specific antigen, PSADT PSA doubling time, Vintage vintage androgen receptor antagonist.
*P < 0.05.